Proactive Investors - Run By Investors For Investors

Redx Pharma - Entering the Clinical Stage

Redx Pharma - Entering the Clinical Stage

Redx Pharma, a drug discovery and development company focused on oncology, immunology and infectious diseases, is about to move its two lead candidates into the clinical stage.

Redx pharma owns RXC005 global IP rights, with key composition-of-matter patents expected to extend up until 2035

Full report is available via Capital Network website

Register here to be notified of future REDX Company articles
View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Researches

April 04 2017

On April 3rd Avacta released the results of a pre-clinical study showing that Affimers have an immunogenicity profile comparable to widely used biotech drugs.  This leaves Avacta on track to move their immuno-oncology therapeutic Affimer into the clinic by 2019.

October 26 2016

Concepta is a small UK-based company that focuses on the development and commercialization of its medical diagnostic device MyLotus. The device, a consumer good, has been developed to improve the probability of conception for women with unexplained infertility (not pregnant after 12+ months trying).

April 03 2017

Sphere Medical is launching Proxima 4, the first patient-attached blood gas and electrolytes (BGE) monitoring system on the market, which could transform the way critically ill patients are treated.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use